Vitae Pharma (VTAE) Announces Statistically Significant Data from VTP-43742 Phase 2a PoC Trial in Psoriatic Patients
Tweet Send to a Friend
Vitae Pharmaceuticals, Inc. (Nasdaq: VTAE) announced positive top-line results from its Phase 2a proof-of-concept clinical trial of VTP-43742 in psoriatic ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
